Navigation Links
Cellestis Responds to World Health Organization Guidance on Use of Blood Tests for Active Tuberculosis
Date:7/25/2011

potentially help to lower healthcare costs related to TB and reduce the risk of epidemics."

QFT is well-regarded by the public health and infectious disease communities, and evidence of its clinical effectiveness and utility in tuberculosis management has been supported over the years in more than 600 peer-reviewed studies published in prestigious medical journals throughout the world.(3,4,5,6,)

About QuantiFERON®-TB Gold (QFT)

QuantiFERON®-TB Gold (QFT) is a whole blood test that accurately identifies people infected with Mycobacterium tuberculosis, the causative agent of Tuberculosis (TB). As a modern alternative to the 110 year old Tuberculin Skin Test (TST), also known as the Mantoux, QFT offers unmatched specificity, high sensitivity and simplicity. QFT enables focused TB therapy by providing clinicians with an accurate, reliable and convenient TB diagnostic tool. QFT is unaffected by previous BCG vaccination and most other environmental mycobacteria. Unlike the TST, it requires only one patient visit, is a controlled laboratory test and provides an objective, reproducible result that is unaffected by subjective interpretation.

QFT is available for use in all clinical settings in which TST is commonly used. Examples include contact tracing, regular employee testing, for example for health care workers, as well as screening programs for prisoners and immigrants. QFT's application in the screening of immunosuppressed patients prior to anti-TNF-alpha therapy initiation and in patients with HIV, cancer or organ transplants offers distinct advantages over the TST.

QFT is sold directly in the U.S. by Cellestis Inc. and through Quest Diagnostics, Inc., LabCorp, and other commercial laboratories. In Europe QFT is provided by Cellestis GmbH (Germany); and in Australia/New Zealand by Cellestis International Pty. Ltd. (Australia). QFT is also available through Cellestis Commercial Partners in Japan, Europe, the M
'/>"/>

SOURCE Cellestis Limited
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Takeda Responds to U.S. Food and Drug Administration Update to Safety Review of ACTOS (pioglitazone HCl)
2. Valeant Pharmaceuticals Responds to Cephalon Boards Letter
3. NCPA Responds to Consumer Groups Request for CVS Caremark Divestiture
4. Mangrove Partners Responds to Erroneous CPEX Assertions
5. Boston Scientific Responds to DOJ Civil Lawsuit
6. CPF Responds to Positive News on First Drug for Treatment for Pulmonary Fibrosis
7. Marken Rapidly Responds to Global Supply Chain Security Measures
8. PhRMA CEO John Castellani Responds to Mid-Term Election, Stresses Importance of Innovation to Help Grow Economy
9. FRCs Jeanne Monahan Responds to Two New Deaths from RU-486
10. Takeda Responds to Announcement about Suspension of Rosiglitazone Marketing Authorization in Europe and Restrictions in the U.S.
11. Atrium Responds to Bard Suit
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2014)... Mass. , Aug. 1, 2014  NxStage Medical, Inc. ... dialysis products, today announced that Jeffrey H. Burbank , ... Officer, will present at the 34 th Annual Canaccord ... Boston, MA , on Wednesday, August 13 th ... will be made available at http://ir.nxstage.com/ .  ...
(Date:8/1/2014)... 2014 Arena Pharmaceuticals, Inc. (NASDAQ: ... and reported financial results for the second quarter ... have continued to see encouraging advancements in the ... increase in estimated total prescriptions and estimated total ... Jack Lief, Arena,s President and Chief Executive Officer. ...
(Date:7/31/2014)... 2014 STAAR Surgical Company (NASDAQ: ... implantable lenses and delivery systems for the eye today ... 2014 of $20.0 million, a 10% increase over $18.2 ... a constant currency basis, revenues grew 11% during the ... of 2013.  The effect of foreign currency exchange reduced ...
Breaking Medicine Technology:NxStage to Present at the 34th Annual Canaccord Genuity Growth Conference 2Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 2Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 3Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 4Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 5Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 6Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 7Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 8Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 9Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 10Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 11STAAR Surgical Reports 10% Second Quarter Revenue Growth 2STAAR Surgical Reports 10% Second Quarter Revenue Growth 3STAAR Surgical Reports 10% Second Quarter Revenue Growth 4STAAR Surgical Reports 10% Second Quarter Revenue Growth 5STAAR Surgical Reports 10% Second Quarter Revenue Growth 6STAAR Surgical Reports 10% Second Quarter Revenue Growth 7STAAR Surgical Reports 10% Second Quarter Revenue Growth 8STAAR Surgical Reports 10% Second Quarter Revenue Growth 9STAAR Surgical Reports 10% Second Quarter Revenue Growth 10STAAR Surgical Reports 10% Second Quarter Revenue Growth 11STAAR Surgical Reports 10% Second Quarter Revenue Growth 12STAAR Surgical Reports 10% Second Quarter Revenue Growth 13STAAR Surgical Reports 10% Second Quarter Revenue Growth 14STAAR Surgical Reports 10% Second Quarter Revenue Growth 15STAAR Surgical Reports 10% Second Quarter Revenue Growth 16STAAR Surgical Reports 10% Second Quarter Revenue Growth 17STAAR Surgical Reports 10% Second Quarter Revenue Growth 18STAAR Surgical Reports 10% Second Quarter Revenue Growth 19STAAR Surgical Reports 10% Second Quarter Revenue Growth 20STAAR Surgical Reports 10% Second Quarter Revenue Growth 21STAAR Surgical Reports 10% Second Quarter Revenue Growth 22STAAR Surgical Reports 10% Second Quarter Revenue Growth 23STAAR Surgical Reports 10% Second Quarter Revenue Growth 24STAAR Surgical Reports 10% Second Quarter Revenue Growth 25
... NEW YORK, June 13, 2011 Reportlinker.com ... is available in its catalogue: ... in Key SADC Countries ... aim of this research service is to ...
... 2011 Science, public health, and regulatory highlights from ... this document is designed for credentialed journalists. Release dates and ... (Logo:   http://photos.prnewswire.com/prnh/20090824/FDALOGO ) ... or enforcement actions due to legal limitations. ...
Cached Medicine Technology:Reportlinker Adds Distributor Analysis of the Pharmaceutical Industry in Key SADC Countries 2Reportlinker Adds Distributor Analysis of the Pharmaceutical Industry in Key SADC Countries 3
(Date:8/1/2014)... HealthDay Reporter THURSDAY, July ... high doses of estrogen, along with some other formulations, ... under 50, new preliminary research suggests. "There ... Beaber, a staff scientist at the Fred Hutchinson Cancer ... breast cancer risk while other formulations do not raise ...
(Date:8/1/2014)... (PRWEB) August 01, 2014 AMTC hosts and ... a.m. and 1 p.m. in three cities on August 9. ... are invited to participate in the free auditions. , ... top actors, models, singers, dancers and comedians. Recently, AMTC grad ... went on to compete for Mrs. World in May 2014. ...
(Date:8/1/2014)... Resources and Services Administration has awarded the LSU ... an Advanced Nursing Education grant in the amount ... support training interprofessional teams of students to improve ... diverse populations with behavioral health disorders and multiple ... Anesthesia Program Director and Associate Professor of Clinical ...
(Date:8/1/2014)... The Gerontological Society of America (GSA) ... the field of aging has chosen J. ... 2014 recipient of the Distinguished Career Contribution to ... annually to an individual whose theoretical contributions have ... or have yielded original and elegant research designs ...
(Date:8/1/2014)... (GSA) the nation,s largest interdisciplinary organization devoted to ... Lewis, PT, DPT, PhD, GTC, GCS, MSG, MPA, FAPTA, ... of Aging Persons Award. , This distinguished honor is ... of rehabilitation. The awardee,s work may be in the ... may include scholarly works, books, monographs, administrative directives, or ...
Breaking Medicine News(10 mins):Health News:Some Birth Control Pills May Up Breast Cancer Risk 2Health News:Some Birth Control Pills May Up Breast Cancer Risk 3Health News:AMTC Announces Three Upcoming Audition Sites for Upcoming Performers 2Health News:LSUHSC Nursing awarded $1 million grant to improve care for veterans 2Health News:Suitor to receive GSA's 2014 Distinguished Career Contribution to Gerontology Award 2Health News:Lewis to receive GSA's 2014 Excellence in Rehabilitation of Aging Persons Award 2
... Ranbaxy Laboratories and Aurobinda Pharma were among some of ... UN Secretary General Kofi Annan // for their ... ,Annan complimented these companies for their efforts ... a meeting with their top executives at United Nations ...
... week of Asian countries, including China, on the global health ... substantial poultry losses and human deaths. ,"Health and ... to the meet here on July 27-28 to study how ... unprecedented in its geographical scope, spread and consequences," said a ...
... has claimed the lives of 271 people this year in ... ,Replying to the debate on cut motions in ... higher as information from interior areas had not reached the ... was "slow", he said this year 90 per cent of ...
... the ‘fat controller’ could offer new hope in treating ... of Dundee have claimed to uncover a link between ... the head of the international research team at Dundee ... of treatment for patients who suffer from these diseases. ...
... a complication, such as a hernia, within 6 months ... by HHS’ Agency// for Healthcare Research and Quality. The ... complications from obesity operations based on insurance claims data. ... among non-elderly obesity surgery patients with private insurance increased ...
... that recycling boxes are unreasonably heavy and could injure anyone ... said that any such injuries could trigger potential lawsuits. The ... could become too heavy when filled with a mixture of ... recommended weight limit. The report, which was compiled after a ...
Cached Medicine News:Health News:India to Host Asian Review Meet on Avian Flu 2Health News:Protein May Offer New Hope For Treatment Of Cystic Fibrosis 2Health News:Obesity Surgery Complication Rates Higher than Previously Thought 2
The AIA-600 II has become the new standard in benchtop immunoassay analyzers....
... The ACON PSA Semi-Quantitative Prostate Specific ... Blood/Serum/Plasma) are lateral flow tests in strip ... of Prostate Specific Antigen (PSA). The tests ... ng/mL cut-off values, and all come with ...
... Assess Functional Vision, Quality of Vision ... controls both target illumination and glare ... testing results. Day/Night testing with/without glare ... Standards and all ANSI standards. All ...
... is Recognized as a Valuable Tool ... by Early Eye Disease. Near Test ... 7 in (12.7cm x 17.78cm) Can ... Refractor,Distance Test F.A.C.T. 201: Size ...
Medicine Products: